Thermo Fisher Q1 Outlook

Thermo Fisher beat Wall Street’s first-quarter estimates on April 23, but its stock fell after management said some research customers are still not coming back this year. (reuters.com) The company reported first-quarter revenue of $11.01 billion for the period ended March 28, 2026, up 6% from a year earlier. Adjusted earnings were $5.44 a share, while GAAP diluted earnings were $4.43 a share. (ir.thermofisher.com) Thermo Fisher also raised its full-year 2026 guidance to $47.3 billion to $48.1 billion in revenue and $24.64 to $25.12 in adjusted earnings per share. Reuters reported analysts had expected about $5.24 a share in the first quarter. (ir.thermofisher.com) (reuters.com) The problem was not the quarter that just ended. It was management’s warning that demand from U.S. academic customers and academic and government customers in China is not expected to recover in 2026. (reuters.com) That weakness hits a business that sells the tools behind lab work: instruments, testing systems, reagents, diagnostics and manufacturing services used by drugmakers, hospitals, universities and government labs. Thermo Fisher says it generates more than $40 billion in annual revenue across those markets. (ir.thermofisher.com) The soft spot showed up most clearly in Analytical Instruments, the segment that serves pharmaceutical, biotechnology, academic, government and industrial customers. On the earnings call, executives said muted instrument demand from academic and government customers in the U.S. and China pushed that segment’s adjusted operating income down 11% and cut margin by 250 basis points to 20.7%. (news.alphastreet.com) Investors reacted to that outlook immediately. Thermo Fisher shares closed April 23 at $466.70, down 9.2% for the day, after opening at $472.65 versus a previous close of $513.98. (finance.yahoo.com) (cnbc.com) The quarter was stronger in other parts of the company. Thermo Fisher said it got growth from lab products and biopharma services, and Chief Executive Marc Casper said in the release that end markets were “progressing in line with our expectations” as the company integrated Clario. (ir.thermofisher.com) Thermo Fisher entered 2026 after reporting $44.56 billion in full-year 2025 revenue and $22.87 in adjusted earnings per share. The new first-quarter results show sales are still growing, but the recovery is uneven enough that one weak customer group can outweigh a headline earnings beat. (ir.thermofisher.com)